BMP-ALK3 antagonists and uses for promoting bone growth

Details for Australian Patent Application No. 2010232693 (hide)

Owner Acceleron Pharma Inc.

Inventors Seehra, Jasbir

Agent Shelston IP

Pub. Number AU-A-2010232693

PCT Pub. Number WO2010/114860

Priority 61/211,557 30.03.09 US; 61/314,556 16.03.10 US; 61/306,331 19.02.10 US

Filing date 30 March 2010

Wipo publication date 7 October 2010

International Classifications

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/10 (2006.01) Drugs for skeletal disorders

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07K 14/51 (2006.01) Peptides having more than 20 amino acids

C07K 16/22 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

Event Publications

3 November 2011 PCT application entered the National Phase

  PCT publication WO2010/114860 Priority application(s): WO2010/114860

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010232694-Method of treating osteoporosis

2010232692-Treatment of insulin-resistant disorders